Statins play an increasing important role in the primary and secondary prevention of cardiovascular disease, since hypercholesteremia has been proven to be the major risk factor for cardiovascular disease. It is one of the most common drug on prescriptions, behind antibiotics. However, with the increasing clinical use, other adverse reactions were found besides on the muscle, liver and kidney. American FDA announces diabetes risk in labeling for some cholesterol-lowering drugs at February 2012. The same year in December, China's FDA made a similar risk warning. Now, new-onset diabetes risk has become one of the most concern about adverse reactions. This review focused on the latest research about new-onset diabetes risk of statins.